Sponsor
Anheart Therapeutics Inc.
1500 Broadway Suite 1401, 10036-4055, United States
About the sponsor
Research activity is centered on non-small cell lung cancer, with a clear focus on advanced and metastatic disease settings. The clinical program addresses ROS1-positive lung cancer, reflecting interest in targeted treatment approaches for molecularly defined patient groups.
- ROS1-positive NSCLC
- Advanced lung cancer
- Metastatic disease
The sponsor’s trial portfolio is concentrated in thoracic oncology, with activity spanning multiple research sites across several countries.
Try clearing a filter, or search the whole catalogue.
Are you running a clinical trial?
Increase visibility for your trials and help patients find your site through our platform.